INVESTOR ALERT: Investigation of NanoViricides, Inc. Announced by Glancy Binkow & Goldberg LLP
February 25 2014 - 6:32PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims on behalf of investors of
NanoViricides, Inc. (“NanoViricides” or the “Company”) (NYSE
MKT:NNVC) concerning possible violations of federal securities
laws. NanoViricides is a nano-biopharmaceutical company engaged in
the discovery, development and commercialization of therapeutics
for the treatment of viral infections. The investigation is focused
on the Company’s business, operations and financial
performance.
Please contact us at (212) 682-5340, Toll-Free at (888)
773-9224, or at shareholders@glancylaw.com to discuss this matter.
If you inquire by email please include your mailing address,
telephone number and number of shares purchased.
The investigation is related to a report published February 11,
2014, on SeekingAlpha alleging that NanoViricides is a “House of
Cards with -80% downside,” and “a vehicle designed specifically to
enrich insiders.” The SeekingAlpha report claims that numerous
examples of certain NanoViricides managers “abusing shareholders
and looting the company” are outlined in a shareholder derivative
complaint, Yidam, Ltd. v. Anil Diwan, et al., Case No.
1:13-cv-01777-RM-BNB, filed July 5, 2013, in the United States
District Court for the District of Colorado.
If you purchased NanoViricides shares, if you have information
or would like to learn more about these claims, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Michael Goldberg,
Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park
East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow &
Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York
10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com. If you inquire by
email, please include your mailing address, telephone number and
number of shares purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CAMichael
Goldberg, 888-773-9224orGlancy Binkow & Goldberg LLP, New York,
NYGregory Linkh, 212-682-5340shareholders@glancylaw.comwww.glancylaw.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Jul 2023 to Jul 2024
